Recent Quotes (30 days)

You have no recent quotes
chg | %

Valeant Pharmaceuticals Intl Inc  

(Public, TSE:VRX)   Watch this stock  
Find more results for VRX
26.05
-0.24 (-0.91%)
Jun 30 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 25.25 - 26.54
52 week 24.32 - 347.84
Open 25.90
Vol / Avg. 1.33M/1.28M
Mkt cap 8.95B
P/E     -
Div/yield     -
EPS -2.76
Shares 341.19M
Beta -0.31
Inst. own 83%
Jul 21, 2016
Q2 2016 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 14, 2016
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting
Jun 10, 2016
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting (Estimated)
Jun 7, 2016
Q1 2016 Valeant Pharmaceuticals International Inc Earnings Release
Jun 7, 2016
Q1 2016 Valeant Pharmaceuticals International Inc Earnings Call
May 23, 2016
Valeant Pharmaceuticals International Inc at UBS Global Healthcare Conference
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -15.72% -2.75%
Operating margin 2.79% 14.43%
EBITD margin - 45.71%
Return on average assets -3.05% -0.76%
Return on average equity -25.92% -5.21%
Employees 22,000 -
CDP Score - -

Address

Laval, 2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

Description

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Officers and directors

Joseph C. Papa Chairman of the Board
Age: 60
Michael Pearson Chief Executive
Robert L. Rosiello Chief Financial Officer, Executive Vice President
Age: 57
Pavel Mirovsky President and General Manager, Europe
Age: 64
Robert Roswell Chai-Onn Executive Vice President, General Counsel and Chief Legal Officer, Head of Corporate and Business Development, Director
Age: 44
Ari S. Kellen Executive Vice President, Company Group Chairman
Age: 51
Laizer D. Kornwasser Executive Vice President, Company Group Chairman
Age: 44
Thomas W. Ross Sr. Lead Independent Director
William A. Ackman Director
Age: 49
Fredric N. Eshelman Independent Director